Phase 3 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a Body Mass Index (BMI) of 25 or above but below 40 (a measure of body weight relative to height)
- People who do not have serious medical problems or chronic diseases, and specifically do not have type 1 or type 2 diabetes
Who may not be able to join:
- People who have another condition that causes stomach or digestive symptoms
- People who have had a bad reaction or sensitivity to a type of medication known as NK-1 receptor antagonists
- People who have had a bad reaction or sensitivity to a type of medication known as GLP-1 receptor agonists (a class of medicines sometimes used for blood sugar or weight management)
- People who have taken part in another medical study and received an experimental medication within the past 60 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc.
Phone: (202) 734-3400
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.